SCHEMBL244632

SCHEMBL244632

Nc1ccncc1C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 7/20 0.70
KDM4E B2RXH2 4/20 0.70
ALDH1A1 P00352 4/20 0.70
TDP1 Q9NUW8 3/20 0.70
KMT2A Q03164 3/20 0.70
KDM6B O15054 3/20 0.70
MEN1 O00255 2/20 0.70
MAPT P10636 2/20 0.70
THRB P10828 2/20 0.70
KDM4D Q6B0I6 2/20 0.70
KDM4A O75164 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
GAA P10253 3/20 0.47
GLA P06280 2/20 0.47
SIRT3 Q9NTG7 1/20 0.47
GFER P55789 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
USP2 O75604 1/20 0.45
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30785801 1.00 KDM4C (0.70) KDM4CKDM4EALDH1A1TDP1KMT2A
SCHEMBL220890 1.00 KDM4C (0.70) KDM4CKDM4EALDH1A1TDP1KMT2A
Ammonia Solution, Strong SCHEMBL11786496 0.98 KDM4C (0.68) KDM4CKDM4EALDH1A1TDP1KMT2A
Ammonia Solution, Strong SCHEMBL11786508 0.98 KDM4C (0.68) KDM4CKDM4EALDH1A1TDP1KMT2A
SCHEMBL11098872 0.84 KDM4C (0.61) KDM4CKDM4EALDH1A1TDP1KMT2A
SCHEMBL29270366 0.83 KDM4C (1.00) KDM4CKDM4EALDH1A1TDP1KMT2A
SCHEMBL310266 0.83 TDP1 (0.62) KDM4CKDM4EALDH1A1TDP1KMT2A
SCHEMBL29643531 0.83 KDM4C (1.00) KDM4CKDM4EALDH1A1TDP1KMT2A
SCHEMBL535569 0.83 KDM4C (1.00) KDM4CKDM4EALDH1A1TDP1KMT2A
SCHEMBL8067971 0.81 KDM4E (0.52) KDM4CKDM4EALDH1A1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1022 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP claimed
CN-118359534-A Sinapic acid derivative and preparation method and application thereof 董豪 2024-07-19 CN claimed
CN-118143871-A High-strength diamond grinding wheel based on PCD (polycrystalline diamond) composite sheet and preparation method thereof 江阴市科雷特工具有限公司 2024-06-07 CN claimed
CN-114998621-B SERS quantitative analysis method based on coffee ring concentration effect and image processing technology 嘉兴学院 2024-04-16 CN claimed
CN-117510404-A Preparation method of 4-aminonicotinic acid 山西永津集团有限公司 2024-02-06 CN claimed
CN-115245816-B Amino-nicotinic acid mixed mode chromatographic stationary phase and preparation method and application thereof 河北工业大学 2024-01-23 CN claimed
US-20240011009-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2024-01-11 US claimed
CN-115403517-B Organic-inorganic hybrid heteropolyacid solid tackifier, preparation method and dealcoholized silicone adhesive 万华化学集团股份有限公司 2023-08-11 CN claimed
US-20230220589-A1 POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF Encodia, Inc. (US) 2023-07-13 US claimed
EP-4127157-A1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS Encodia, Inc. (US) 2023-02-08 EP claimed
US-8591636-B2 Plating catalyst and method ROHM AND HAAS ELECTRONICS MATERIALS LLC (US) 2013-11-26 US claimed
CN-102786468-A Nicotinic acid derivative having GK (glucokinase) and PPAR (peroxidase proliferator-activated receptor) dual agonist activities INST MATERIA MEDICA CAMS 2012-11-21 CN claimed
US-20120014918-A1 ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS ALMIRALL, S.A. (ES) 2012-01-19 US claimed
EP-2406225-A1 ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS Almirall S.A. (ES) 2012-01-18 EP claimed
EP-2345713-A1 A CONCENTRATED CULTURE SOLUTION AND APPLICATION METHOD THEREOF Shanghai CP Guojian Pharmaceutical Co. Ltd (CN) 2011-07-20 EP claimed
US-20110111495-A1 CONCENTRATED MEDIUM AND ITS USAGE SHANGHAI CP GUOJIAN PHARMACEUTICAL CO. LTD (CN) 2011-05-12 US claimed
CN-100340558-C N,N-dipyridyl 3,4,9,10-tetraformyl diimine derirative and its synthesis method UNIV DONGNAN (CN) 2007-10-03 CN claimed
CN-100340560-C N,N'-dipyridyl-equibenzyl-tetraformyldiimine derivative and its synthesis method UNIV SOUTHEAST (CN) 2007-10-03 CN claimed
CN-1785998-A N,N-dipyridyl 3,4,9,10-tetraformyl diimine derirative and its synthesis method UNIV DONGNAN (CN) 2006-06-14 CN claimed
CN-1763041-A N,N'-dipyridyl-equibenzyl-tetraformyldiimine derivative and its synthesis method UNIV SOUTHEAST (CN) 2006-04-26 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014918-A1 ADDITION SALTS OF AMINES CONTAINING HYDROXYL AND/OR CARBOXYLIC GROUPS WITH AMINO NICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS DHODH, DAO, ADH1B KDM4C 3281/4885KDM4E 3178/4885ALDH1A1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.